Pharmacy Benefit Manager CVS Health, which has over 90 million members, has released the results of a survey it conducted of approximately 2000 people in the United States concerning patient perceptions of generic and biosimilar medications.
Pharmacy Benefit Manager (PBM) CVS Health, which has over 90 million members, has released the results of a survey it conducted of approximately 2000 people in the United States concerning patient perceptions of generic and biosimilar medications.
Of the respondents, 60% reported taking prescription drugs. Among that group:
Overall, the survey demonstrated acceptance of generic drugs:
Some respondents also saw the potential to benefit from biosimilar medications:
CVS Health notes that, in 2016, clients who used the company’s generics-focused formulary saw an 88.2% increase in the rate of dispensed generics (3.2% higher than the rate for clients using the PBM’s standard formulary). The PBM expects to generate $13.4 billion in savings for its clients over the 2012 to 2018 period through including more low-cost drugs on its formularies, encouraging patients to switch to available generics, and including biosimilars in its formulary strategy.
The PBM says that specialty pharmaceuticals, including biologics, are responsible for approximately 36% of its total spending, and cited RAND Corporations projection that biosimilars in the specialty marketplace could reduce spending on biologics by $44.2 billion over the coming 10 years. Last year, CVS Health indicated its intention to move toward greater biosimilar use to reap some of those savings: its 2017 formulary employed biosimilar filgrastim (Zarxio) as a replacement for its reference (Neupogen). It also replaced reference insulin glargines (Lantus and Toujeo) with a follow-on (Basaglar). In its 2018 formulary, the PBM stopped short of including the newly launched biosimilar infliximab (Renflexis), but noted that “The autoimmune class is a leading trend driver for commercial clients,” and said that it will evaluate its formulary in light of new product entries.
The American Medical Association (AMA) responded to CVS Health’s shift toward biosimilars last year with a call for patient and practitioner choice: AMA president Andrew Gurman, MD, said that “Patients should have the opportunity to choose from a wide range of available therapies. Certainly, biosimilars show great promise, but ultimately, it is important that the patient and his or her physician maintain the ability to choose the best therapy for that particular patient and situation.”
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.